Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 365-371

  Meek, I L ^a   Vonkeman, H E ^a   Kasemier, J ^a   Movig, K L L ^a   Van De Laar, M A F J ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Aspirin; Coagulation; NSAID; Pharmacology; Platelets; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLZUUR CARDIO DISP; CYCLOOXYGENASE 1; ETORICOXIB; IBUPROFEN; MELOXICAM; NAPROXEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; HEARTBURN; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH PAIN; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NAPROXEN; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PYRIDINES; RISK ASSESSMENT; SULFONES; THIAZINES; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84877106546     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1370-y     Document Type: Article

References (33)

1. Al-Windi A (2005) Determinants of medicine use in a Swedish primary health care practice population. Pharmacoepidemiol Drug Saf 14(1):47-51
2. Nobili A, Franchi C, Pasina L et al (2011) Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf 20(5):488-496
3. Pilotto A, Franceschi M, Leandro G, Di Mario F (2003) NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20(9):701-710
4. Dorp V, Beerthuis RK, Nugteren DH, Vonkeman H (1964) The biosynthesis of prostaglandins. Biochim Biophys Acta 90:204-207
5. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265(28):16737-16740
6. Van Hecken A, Schwartz JI, Depre M et al (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40(10):1109-1120
7. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353(9149):307-314
8. Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809-1817
9. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 157(6):931-934
10. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101(7):1060-1063
11. Capone ML, Sciulli MG, Tacconelli S et al (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45(8):1295-1301
12. Anzellotti P, Capone ML, Jeyam A et al (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 63(3):850-859
13. Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10):1191-1195
14. MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573-574
15. Kimmel SE, Strom BL (2003) Giving aspirin and ibuprofen after myocardial infarction. BMJ 327(7427):1298-1299
16. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM (2003) Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327(7427):1322-1323
17. Patel TN, Goldberg KC (2004) Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 164(8):852-856
18. Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086
19. Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and Knee. Arthritis Care Res 64(4):455-474
20. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, American Heart Association (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115(12):1634-1642
21. Rodriguez TAG, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52(20):1628-1636
22. Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130(3):465-472
23. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B (2007) Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 120(2):161-172
24. Vonkeman HE, Van de Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39(4):294-312
25. Catella-Lawson F, Crofford LJ (2001) Cyclooxygenase inhibition and thrombogenicity. Am J Med 110(Suppl 3A):28S-32S
26. de Gaetano G, Cerletti C, Dejana E, Latini R (1985) Pharmacology of platelet inhibition in humans: implications of the salicilate-aspirin interaction. Circulation 72:1185-1193
27. Awa K, Satoh H, Hor S, Sawada Y (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 37:469-474
28. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28(14):1702-1708
29. Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9(5):407-415
30. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, De Gaetano G (2008) Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 99(1):14-26
31. Andersen K, Hurlen M, Arnesen H, Seljeflot I (2002) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108(1):37-42
32. Poulsen TS, Jorgensen B, Korsholm L, Bjorn LP, Haghfelt T, Mickley H (2007) Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 119(5):555-562
33. Gurbel PA, Tantry US (2007) Clopidogrel resistance? Thromb Res 120(3):311-321